These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 27092342)
1. The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year. Graul AI; Cruces E; Dulsat C; Tracy M Drugs Today (Barc); 2016 Feb; 52(2):131-63. PubMed ID: 27092342 [TBL] [Abstract][Full Text] [Related]
2. The year's new drugs & biologics 2016: Part II - Trends and highlights of an unforgettable year. Graul AI; Dulsat C; Tracy M; Cruces E Drugs Today (Barc); 2017 Feb; 53(2):117-158. PubMed ID: 28387389 [TBL] [Abstract][Full Text] [Related]
3. The year's new drugs & biologics, 2017, part II - News that shaped the industry in 2017. Graul AI; Dulsat C; Pina P; Tracy M; D'Souza P Drugs Today (Barc); 2018 Feb; 54(2):137-167. PubMed ID: 29637939 [TBL] [Abstract][Full Text] [Related]
4. The year's new drugs and biologics 2018: Part II - News that shaped the industry in 2018. Graul AI; Dulsat C; Pina P; Cruces E; Tracy M Drugs Today (Barc); 2019 Feb; 55(2):131-160. PubMed ID: 30816887 [TBL] [Abstract][Full Text] [Related]
5. The year's new drugs & biologics, 2013: Part II. Graul AI; Navarro D; Dulsat C; Cruces E; Tracy M Drugs Today (Barc); 2014 Feb; 50(2):133-58. PubMed ID: 24619590 [TBL] [Abstract][Full Text] [Related]
7. The year's new drugs & biologics, 2010. Graul AI; Cruces E Drugs Today (Barc); 2011 Jan; 47(1):27-51. PubMed ID: 21373648 [TBL] [Abstract][Full Text] [Related]
8. The year's new drugs and biologics--2007. Graul AI; Prous JR; Barrionuevo M; Bozzo J; Castaner R; Cruces E; Revel L; Rosa E; Serradell N; Sorbera LA Drug News Perspect; 2008; 21(1):7-35. PubMed ID: 18301807 [TBL] [Abstract][Full Text] [Related]
9. The year's new drugs and biologics--2006. Graul AI; Sorbera LA; Bozzo J; Serradell N; Revel L; Prous JR Drug News Perspect; 2007; 20(1):17-44. PubMed ID: 17332898 [TBL] [Abstract][Full Text] [Related]
10. The year's new drugs & biologics, 2014: Part I. Graul AI; Cruces E; Stringer M Drugs Today (Barc); 2015 Jan; 51(1):37-87. PubMed ID: 25685860 [TBL] [Abstract][Full Text] [Related]
11. The year's new drugs & biologics - 2008. Graul AI; Revel L; Barrionuevo M; Cruces E; Rosa E; Verges C; Lupone B; Diaz N; Castaner R Drug News Perspect; 2009; 22(1):7-29. PubMed ID: 19209296 [TBL] [Abstract][Full Text] [Related]
12. The Year's New Drugs & Biologics - 2009. Graul AI; Sorbera L; Pina P; Tell M; Cruces E; Rosa E; Stringer M; Castañer R; Revel L Drug News Perspect; 2010; 23(1):7-36. PubMed ID: 20155217 [TBL] [Abstract][Full Text] [Related]
13. Priorities for the Priority Review Voucher. Ridley DB Am J Trop Med Hyg; 2017 Jan; 96(1):14-15. PubMed ID: 27573624 [TBL] [Abstract][Full Text] [Related]
14. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help. Waxman H; Corr B; Martin K; Duong S Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802 [TBL] [Abstract][Full Text] [Related]
15. 2012 in review - part I: the year's new drugs & biologics. Graul AI; Lupone B; Cruces E; Stringer M Drugs Today (Barc); 2013 Jan; 49(1):33-68. PubMed ID: 23362494 [TBL] [Abstract][Full Text] [Related]
16. The Tropical Disease Priority Review Voucher: A Game-Changer for Tropical Disease Products. Berman J; Radhakrishna T Am J Trop Med Hyg; 2017 Jan; 96(1):11-13. PubMed ID: 27573627 [TBL] [Abstract][Full Text] [Related]
17. The year's new drugs & biologics 2015: Part I. Graul AI; Cruces E; Stringer M Drugs Today (Barc); 2016 Jan; 52(1):41-89. PubMed ID: 26937494 [TBL] [Abstract][Full Text] [Related]
18. The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases. Sachs-Barrable K; Conway J; Gershkovich P; Ibrahim F; Wasan KM Drug Dev Ind Pharm; 2014 Nov; 40(11):1429-34. PubMed ID: 24512098 [TBL] [Abstract][Full Text] [Related]
19. Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary Market. Robertson AS Am J Law Med; 2016 May; 42(2-3):524-542. PubMed ID: 29086641 [TBL] [Abstract][Full Text] [Related]
20. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021. Monge AN; Sigelman DW; Temple RJ; Chahal HS JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]